Jiske Fermont

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

John Foley, Gilles Defer, Lana Zhovtis Ryerson et al. · The Lancet Neurology · 2022 · 103 citations

Relapsing-remitting Multiple Sclerosis, Clinical Neurology, Clinical Trials +8

Prevalence and distribution of fasciculations in healthy adults: Effect of age, caffeine consumption and exercise

Jiske Fermont, Ilse M.P. Arts, Sebastiaan Overeem et al. · Amyotrophic Lateral Sclerosis · 2010 · 55 citations

Physical Activity, Obesity, Kinesiology +16

Disease impact in chronic progressive external ophthalmoplegia: More than meets the eye

Bart W. Smits, Jiske Fermont, Cathérine C.S. Delnooz et al. · Neuromuscular Disorders · 2011 · 31 citations · Full text

Diabetic Retinopathy, Ocular Disease, Ophthalmology +6